PT - JOURNAL ARTICLE AU - Selena Y. Lin AU - Yih-Ping Su AU - Evan R. Trauger AU - Benjamin P. Song AU - Emilie G. C. Thompson AU - Malcolm C. Hoffman AU - Ting-Tsung Chang AU - Yih-Jyh Lin AU - Yu-Lan Kao AU - Yixiao Cui AU - Hie-Won Hann AU - Grace Park AU - Wei Song AU - Ying-Hsiu Su TI - Detection of hepatitis B virus-host junction sequences in urine of infected patients AID - 10.1101/2021.04.28.21254562 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.28.21254562 4099 - http://medrxiv.org/content/early/2021/04/29/2021.04.28.21254562.short 4100 - http://medrxiv.org/content/early/2021/04/29/2021.04.28.21254562.full AB - Background & Aims Integrated hepatitis B virus (HBV) DNA, found in >85% of HBV-associated hepatocellular carcinomas (HBV-HCC), can play a significant role in HBV-related liver disease progression. HBV-host junction sequences (HBV-JS’s), created through integration events, have been used to determine HBV-HCC clonality. Here, we investigate the feasibility of analyzing HBV integration in a noninvasive urine liquid biopsy.Approach & Results Utilizing an HBV-targeted NGS assay, we first identified HBV-JS’s in 8 HBV-HCC tissues and designed short-amplicon junction-specific PCR assays to detect HBV-JSs in matched urine. We detected and validated tissue-derived junctions in 5 of 8 matched urine samples. Next, we screened 32 urine samples collected from 25 HBV-infected patients (5 with hepatitis, 10 with cirrhosis, 4 with HCC, and 6 post-HCC). Encouragingly, all 32 urine samples contained HBV-JS’s detectable by HBV-targeted NGS. Of the 712 total HBV-JS’s detected in urine, 351 were in gene-coding regions, 11 of which, including TERT, had previously been reported as recurrent integration sites in HCC tissue and were found in urine of cirrhosis or HCC patients only. The integration breakpoints of HBV DNA detected in urine were found predominantly (∼70%) at a previously identified integration hotspot, HBV DR1-2.Conclusions HBV viral-host junction DNA can be detected in urine of HBV-infected patients. This study is the first study to demonstrate the potential for a noninvasive urine liquid biopsy of integrated HBV DNA to monitor HBV-infected patients for HBV-associated liver diseases and the efficacy of antiviral therapy.Competing Interest StatementS.Y.L. and W.S. are employees and stockholders of JBS Science.Funding StatementThis work was supported by the National Institute of Health grants R43 CA165312 (WS), R44 CA165312 (SL and WS), and R43 CA192507 (WS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Heartland Institutional Review Board (protocol #171201-173). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe sequence data for the subjects studied in this work who consented to data archiving have been deposited in the European Genome Phenome Archive (EGA), www.ebi.ac.uk/ega, which is hosted by the European Bioinformatics Institute (EBI) www.ebi.ac.uk (accession no. pending).HBVhepatitis B virusHBV-HCCHBV-infected hepatocellular carcinomasHBV-JS’sHBV-host junction sequencesHCChepatocellular carcinomacfDNAcell-free DNAUMTunique molecular tagRErestriction endonucleasentnucleotide